MediciNova Receives New Patent Covering MN-221 in Irritable Bowel Syndrome

MediciNova Receives New Patent Covering MN-221 in Irritable Bowel Syndrome

SAN DIEGO, Nov. 11, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a
biopharmaceutical company that is publicly traded on the NASDAQ Global Market
(Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number:
4875), announced that a new U.S. patent has been granted which covers MN-221
in the treatment of irritable bowel syndrome.

The new patent (U.S. Patent No. 8,518,995) will expire no earlier than April
2031. The claims cover a method for treatment of irritable bowel syndrome
using certain compounds including MN-221. The claims cover various routes of
administration including oral, injectable and transdermal.

"We are very pleased that this new patent has been granted as we believe it
will substantially increase the potential value of MN-221," said Yuichi Iwaki,
MD, PhD, President and CEO of MediciNova, Inc. "The new patent allows us the
flexibility to consider pursuit of another indication for MN-221 in future

About Irritable Bowel Syndrome (IBS)

Irritable bowel syndrome is a functional gastrointestinal (GI) disorder,
meaning it is a problem caused by changes in how the GI tract works. The pain
or discomfort of IBS may occur with a change in stool frequency or consistency
or may be relieved by a bowel movement. Irritable bowel syndrome is estimated
to affect 10 to 15 percent of the population.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon
acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet medical needs with a commercial focus on the U.S.
market. MediciNova's current strategy is to focus on its two prioritized
product candidates, MN-166 (ibudilast) for neurological disorders, and MN-221
for the treatment of acute exacerbations of asthma. MN-166 is being developed
in multiple indications, largely through investigator-sponsored trials and
outside funding. MediciNova is engaged in strategic partnering and consortium
funding discussions to support further development of both the MN-221 and
MN-166 programs. For more information on MediciNova, Inc., please visit

Statements in this press release that are not historical in nature constitute
forward-looking statements within the meaning of the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, without limitation, statements regarding the future
development and value of MN-221 and the implication that the company will have
the ability to execute on its priorities. These forward-looking statements may
be preceded by, followed by or otherwise include the words "believes,"
"expects," "anticipates," "intends," "estimates," "projects," "can," "could,"
"may," "will," "would," or similar expressions. These forward-looking
statements involve a number of risks and uncertainties that may cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these forward-looking
statements include, but are not limited to, risks of obtaining future partner
or grant funding for development of MN-221, MN-166 and MN-029 and risks of
raising sufficient capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties inherent in
clinical trials, including the potential cost, expected timing and risks
associated with clinical trials designed to meet FDA guidance and the
viability of further development considering these factors, product
development and commercialization risks, the uncertainty of whether the
results of clinical trials will be predictive of results in later stages of
product development, the risk of delays or failure to obtain or maintain
regulatory approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual property rights
in product candidates and the ability to defend and enforce such intellectual
property rights, the risk of failure of the third parties upon whom MediciNova
relies to conduct its clinical trials and manufacture its product candidates
to perform as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical trials or
significant issues regarding the adequacy of clinical trial designs or the
execution of clinical trials, and the timing of expected filings with the
regulatory authorities, MediciNova's collaborations with third parties, the
availability of funds to complete product development plans and MediciNova's
ability to obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties described in
MediciNova's filings with the Securities and Exchange Commission, including
its annual report on Form 10-K for the year ended December 31, 2012 and its
subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not
be placed on these forward-looking statements, which speak only as of the date
hereof. MediciNova disclaims any intent or obligation to revise or update
these forward-looking statements.

         Geoff O'Brien
         Vice President
         MediciNova, Inc.

MediciNova, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.